-

National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (OTC: NSTGQ), a leading provider of life science tools for discovery and translational research, today announced that research using the company’s CosMx™ Spatial Molecular Imager (SMI) has been featured for a third time in National Geographic Magazine.

A special-interest magazine from National Geographic called Anti-Inflammation, available on newsstands this week, spotlights the role of inflammation on health and disease. The article, “How to Slow Down the March of Time,” features research on senescent “zombie” cells from the lab of Dr. Miranda Orr, associate professor of Gerontology and Geriatric Medicine at Wake Forest University School of Medicine and a research scientist at the W.G. Hefner VA Medical Center in Salisbury, NC.

“Our work focuses on understanding how and why the risk of neurodegenerative diseases increases with advanced age. We discovered that senescent cells, which accumulate with aging, contribute to brain diseases including Alzheimer’s. In clinical trials, we are examining potential therapeutic interventions that clear these toxic cells in patients with Alzheimer’s disease. The visualizations and data achieved with the CosMx SMI instrument provide unprecedented subcellular information across brain regions impacted by Alzheimer’s disease. The technology allows us to characterize these cells and search for new therapeutic targets to clear them, a vital aspect of our progress,” said Dr. Orr.

Senescent cells are those cells that have stopped dividing but remain active and can release substances believed to cause inflammation and damage to nearby healthy cells. Previous research by Orr’s lab identified that the brains of people with Alzheimer’s disease have more senescent cells than healthy people.

“Imagery is an integral part of storytelling at National Geographic. By using these amazing images to help explain the science behind inflammation, we hope to generate more awareness of the promising research on how inflammation affects brain health, a major global health concern,” said Lori Cuthbert, senior editor at National Geographic Magazine.

“It’s tremendously motivating to all of us at NanoString to see CosMx SMI images contribute to the public’s understanding of inflammation and its role in disease. Few publications offer the expansive access to science that National Geographic offers its readers, and we are pleased to see this groundbreaking research with CosMx SMI highlighted in the magazine,” added Brad Gray, President and CEO of NanoString.

About NanoString

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.

For more information, visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, AtoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

This news release may include information regarding CosMx™ SMI products for RNA detection, products that are not available in the Federal Republic of Germany. Such limitations are further described here.

Contacts

Meg O’Conor
Director, Public Relations
moconor@nanostring.com
Phone: 206-602-1768

NanoString Technologies, Inc. LogoNanoString Technologies, Inc. Logo

NanoString Technologies, Inc.

OTC Pink:NSTGQ

Release Versions

Contacts

Meg O’Conor
Director, Public Relations
moconor@nanostring.com
Phone: 206-602-1768

Social Media Profiles
More News From NanoString Technologies, Inc.

NanoString Technologies to Be Acquired by Bruker Corporation

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (“NanoString” or “the Company”), a leading provider of life science tools for discovery and translational research, today announced that substantially all of its assets will be acquired by Bruker Corporation (“Bruker”), a global life science analytical instrument company, for approximately $392.6 million in cash consideration, plus the assumption of certain liabilities. Following the closing, NanoString’s business operations will no longer...

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas. The conference will be held in San Diego, April 5-10, 2024. NanoString and its customers will showcase 110 posters and highlight its products...

Patient Square Capital, a Leading Health Care-Focused Investment Firm, Agrees to Acquire NanoString Technologies

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (OTC: NSTGQ) (“NanoString” or the “Company”), a leading provider of life science tools for discovery and translational research, today announced that it has reached an agreement with Patient Square Capital (“Patient Square”), a prominent health care investment firm, pursuant to which Patient Square will serve as the “stalking horse” bidder in conjunction with a court-supervised sales process. Under the terms of the agreement, Patient Squar...
Back to Newsroom